Melanoma

New Study of an AI-Powered Spectroscopy Device Shows Promise for Skin Cancer Detection

MIAMI--(BUSINESS WIRE)--DermaSensor Inc. – Skin cancer is a global health concern, with increasing incidence rates worldwide. Artificial Intelligence (AI) is…

1 year ago

Alpha Tau Submits to Japanese PMDA for Pre-Market Approval of Alpha DaRT in Patients with Recurrent Head and Neck Cancer

JERUSALEM, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau") (NASDAQ: DRTS, DRTSW), the developer of the…

1 year ago

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business UpdateEnrollment completed for…

1 year ago

Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights

Cash runway extended through multiple data readouts and into Q1 of calendar 2025 MDNA11 is generally well tolerated and continues…

1 year ago

IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update

Advances Non-Viral DNA-Mediated Cancer Immunotherapy and Next-Generation Vaccine Programs, with More Potent and Durable Immunity, with Multiple Near-Term Milestones Conference…

1 year ago

Immatics Announces Third Quarter 2023 Financial Results and Business Update

ACTengine® IMA203 GEN1 TCR-T targeting PRAME showed 50% (6/12) confirmed ORR in melanoma patients with median duration of response (mDOR)…

1 year ago

Defence’s Successful Submission of an Investigational New Drug (IND) Application for AccuTOX(R) as an Injectable Anticancer Treatment for Solid Tumors

Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - Defence Therapeutics Inc. (CSE: DTC) (OTC Pink: DTCFF) (FSE: DTC) ("Defence"…

1 year ago

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target…

1 year ago

IO Biotech Announces 2023 Third Quarter Results

Completed enrollment of 380 patients in pivotal Phase 3 trial of lead therapeutic cancer vaccine, IO102-IO103 in combination with KEYTRUDA®…

1 year ago

Provectus Biopharmaceuticals Provides Updated Data on Cancer Immunotherapy PV-10 for Metastatic Uveal Melanoma

KNOXVILLE, TN, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updated data from an ongoing Phase 1…

1 year ago